1. Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02)
- Author
-
García, Felipe, Bernaldo de Quirós, Juan Carlos López, Gómez, Carmen E., Perdiguero, Beatriz, Nájera, Jose L., Jiménez, Victoria, García-Arriaza, Juan, Guardo, Alberto C., Pérez, Iñaki, Díaz-Brito, Vicens, Conde, Matilde Sánchez, González, Nuria, Alvarez, Amparo, Alcamí, José, Jiménez, José Luis, Pich, Judit, Arnaiz, Joan Albert, Maleno, María J., León, Agathe, and Muñoz-Fernández, María Angeles
- Subjects
- *
AIDS vaccines , *AIDS prevention , *VACCINIA , *GENETIC vectors , *PROTEINS , *CLINICAL trials , *BLIND experiment , *PLACEBOS - Abstract
Abstract: Background: To investigate the safety and immunogenicity of a modified vaccinia virus Ankara vector expressing HIV-1 antigens from clade B (MVA-B), a phase-I, doubled-blind placebo-controlled trial was performed. Methods: 30 HIV-uninfected volunteers at low risk of HIV-1 infection were randomly allocated to receive 3 intramuscular injections (1×108 pfu/dose) of MVA-B (n =24) or placebo (n =6) at weeks 0, 4 and 16. All volunteers were followed 48 weeks. Primary end-points were adverse events and immunogenicity. Results: A total of 169 adverse events were reported, 164 of grade 1–2, and 5 of grade 3 (none related to vaccination). Overall 75% of the volunteers showed positive ELISPOT responses at any time point. The magnitude (median) of the total responses induced was 288SFC/106 PBMC at week 18. Antibody responses against Env were observed in 95% and 72% of vaccinees at week 18 and 48, respectively. HIV-1 neutralizing antibodies were detected in 33% of volunteers. Conclusions: MVA-B was safe, well tolerated and elicited strong and durable T-cell and antibody responses in 75% and 95% of volunteers, respectively. These data support further exploration of MVA-B as an HIV-1 vaccine candidate. Clinical Trials.gov identifier: NCT00679497. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF